Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol MDI with HFA-152a vs HFA-134a propellants in healthy volunteers
NCT06433908Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of salbutamol in asthma (2 cohorts), sponsored by GSK. Primary endpoints: Area Under the Plasma Concentration-time Curve up to 30 Minutes Post-Dose, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at 24 hours and 1 more. Started Jun 2024; status: completed.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06433908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06433908.